227 related articles for article (PubMed ID: 37163358)
1. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study.
Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Shu X; Li C; Dimopoulos M
Blood Adv; 2023 Jul; 7(14):3739-3748. PubMed ID: 37163358
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.
Suzuki K; Min CK; Kim K; Lee JJ; Shibayama H; Ko PS; Huang SY; Li SS; Ding B; Khurana M; Iida S
Int J Hematol; 2021 Dec; 114(6):653-663. PubMed ID: 34410635
[TBL] [Abstract][Full Text] [Related]
5. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
Landgren O; Weisel K; Rosinol L; Touzeau C; Turgut M; Hajek R; Mollee P; Kim JS; Shu N; Hu X; Li C; Usmani SZ
Br J Haematol; 2022 Sep; 198(6):988-993. PubMed ID: 35608261
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
Siegel D; Weisel K; Zahlten-Kumeli A; Medhekar R; Ding B; Leleu X
Leuk Lymphoma; 2021 Dec; 62(12):3002-3010. PubMed ID: 34180331
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of weekly carfilzomib (70 mg/m
Leleu X; Beksac M; Chou T; Dimopoulos M; Yoon SS; Prince HM; Pour L; Shelekhova T; Chari A; Khurana M; Zhang J; Obreja M; Qi M; Oriol A; Siegel D
Leuk Lymphoma; 2021 Feb; 62(2):358-367. PubMed ID: 33112184
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib 56 mg/m
Weisel K; Nooka AK; Terpos E; Spencer A; Goldschmidt H; Dirnberger F; DeCosta L; Yusuf A; Kumar S
Leuk Lymphoma; 2022 Aug; 63(8):1887-1896. PubMed ID: 35289710
[TBL] [Abstract][Full Text] [Related]
11. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
Martin T; Mikhael J; Hajek R; Kim K; Suzuki K; Hulin C; Garg M; Quach H; Sia H; George A; Konstantinova T; Risse ML; Asset G; Macé S; van de Velde H; Moreau P
Blood Adv; 2022 Aug; 6(15):4506-4515. PubMed ID: 35594559
[TBL] [Abstract][Full Text] [Related]
12. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
[TBL] [Abstract][Full Text] [Related]
13. Isatuximab plus carfilzomib and dexamethasone in patients with early
Facon T; Moreau P; Baker R; Min CK; Leleu X; Mohty M; Karlin L; Armstrong NM; Tekle C; Schwab S; Risse ML; Martin T
Haematologica; 2024 Feb; 109(2):604-616. PubMed ID: 37584290
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of weekly carfilzomib 70 mg/m
Puertas B; González-Calle V; Sureda A; Moreno MJ; Oriol A; González E; Rosiñol L; López J; Escalante F; Martínez-Lopez J; Carrillo E; Clavero E; Ríos-Tamayo R; Rey-Bua B; González-Rodríguez AP; Dourdil V; De Arriba F; González S; Pérez-de-Oteyza J; Hernández MT; García-Mateo A; Bargay J; Bladé J; Lahuerta JJ; San Miguel JF; Ocio EM; Mateos MV
Haematologica; 2023 Oct; 108(10):2753-2763. PubMed ID: 37102598
[TBL] [Abstract][Full Text] [Related]
17. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
Blood Cancer J; 2023 May; 13(1):72. PubMed ID: 37156782
[TBL] [Abstract][Full Text] [Related]
18. Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Richter J; Lin PL; Garcia-Horton V; Guyot P; Singh E; Zhou ZY; Sievert M; Taiji R
Cancer Med; 2023 Apr; 12(7):8005-8017. PubMed ID: 36726287
[TBL] [Abstract][Full Text] [Related]
19. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
